rezafungin (Cidara Therapeutics)
86
Structured Review
Cidara Therapeutics
rezafungin
Rezafungin, supplied by Cidara Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rezafungin/rezafungin/pm41580141-31-12-14
Average 86 stars, based on 1 article reviews
Rezafungin, supplied by Cidara Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rezafungin/rezafungin/pm41580141-31-12-14
Average 86 stars, based on 1 article reviews
rezafungin - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Labeling:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Derivative Assay:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Cell Culture:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Modification:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Sterility:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Infection:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Imaging:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Clinical Proteomics:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: Sampling:Article Title: Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study Article Snippet: Article Title: Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin. Article Snippet: Article Title: FDA-Approved Antibacterials and Echinocandins. Article Snippet: Rezafungin was developed by Article Title: Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects. Article Snippet: |
